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Abstract  
An index of fatal toxicity for new psychoactive substances (NPS) has been developed based 
solely on information provided on death certificates. An updated index of fatal toxicity (Tf), 
as first described in 2010 (King and Corkery, 2010), was calculated based on the ratio of 
deaths to prevalence and seizures for the original five substances (amphetamine, cannabis, 
cocaine/crack, heroin and MDMA)1. These correlated well with the 2010 index. Deaths were 
then examined both for cases where the substance was and was not found in association with 
other substances. This ratio (Sole to All mentions; S/A) was then calculated for deaths in the 
period 1993 to 2016. 
 
This new measure of fatal toxicity, expressed by S/A, was well-correlated with the index 
Ln(Tf) of the original reference compounds. The calculation of S/A was then extended to a 
group of NPS where insufficient prevalence or seizure data were available to directly 
determine a value of Tf. by interpolation of a graph of Tf versus S/A. 
 
Benzodiazepine analogues (BZD) had particularly low values of S/A and hence Tf. By 
contrast, γ-hydroxybutyrate/γ-butyrolactone (GHB/GBL), AMT, synthetic cannabinoid 
receptor agonists (SCRAs) and benzofurans had a higher fatal toxicity. 
 
                                                 
1 Although mortality data were available for many substances over the period 1993 to 2016, prevalence data 
from the British Crime Survey, later the Crime Survey for England and Wales, were only available from 2001/2. 
Currently, seizure data are only available for drugs once they are controlled under the Misuse of Drugs Act 
1971. 
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Abbreviations (see also Table 1) 
5F-ADB: aka 5F-MDMB-PINACA:  
5F-AKB-48: N-(1-Adamantyl)-1-(5-fluoropentyl)-1H-indazole-3 –carboxamide 
5F-PB-22: Quinolin-8-yl 1-pentyfluoro-1H-indole-3-8-carboxylate 
AB-CHMINACA: N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-
indazole-3-carboxamide 
AH-7921: 3,4-Dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide 
AMT: α-Methyltryptamine 
APB: Aminopropylbenzofuran aka 1-(1-Benzofuran-2-yl)propan-2-amine 
APDB: 5-(2-Aminopropyl)-2,3-dihydrobenzofuran 
BCS: British Crime Survey 
BZP:1-Benzylpiperazine 
CSEW: Crime Survey for England and Wales 
5-EAPB: 1-(1-Benzofuran-5-yl)-N-ethylpropan-2-amine 
GHB/GBL: γ-Hydroxybutyrate/γ-butyrolactone 
MDDA: aka MDDM and MDDMA; 3,4-Methylenedioxy-N,N-dimethylamphetamine 
MDMA: 3,4-Methylenedioxymethamphetamine 
MDMB-CHMICA: N-[[1-(Cyclohexylmethyl)-1H-indol-3-yl]carbonyl]-3-methyl-valine, 
methyl ester 
MPA: Methiopropamine 
NBOMe derivatives: N-(Methoxybenzyl) phenethylamine derivatives (e.g. 25I-NBOMe) 
NPS: New Psychoactive Substance 
ONS: Office for National Statistics 
PMA: para-Methoxyamphetamine 
PMMA: para-Methoxy-N-methylamphetamine 
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SCRA: Synthetic cannabinoid receptor agonists 
TFMPP: 1-(3-Trifluoromethylphenyl)piperazine 
U-47700: 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide 
 
 
Introduction 
New psychoactive substances (NPS) have been associated with a range of serious harms in 
Europe including deaths (EMCDDA, 2017). The number of fatalities associated with NPS 
appears to be increasing across the United Kingdom (NISRA, 2016; NRS, 2017; ONS, 
2017a). This raises the question of how we might determine their lethal toxicity compared 
with better-known drugs. The intrinsic fatal toxicity of a substance cannot simply be equated 
to the number of deaths associated with that substance; a suitable denominator of the extent 
of use or availability is usually required. With licensed medicines, it was found over thirty 
years ago that an index of fatal toxicity (T) could be created by relating the number of deaths 
associated with a certain substance to its availability measured by the number of prescriptions 
issued (King and Moffat, 1981; King and Moffat, 1983). Since that method is not appropriate 
for illicit substances, a different approach is needed. Measures of availability such as law 
enforcement seizures, estimates of market size and prevalence, as judged by household 
surveys, were used to provide an alternative index of fatal toxicity (King and Corkery, 2010). 
However, for many NPS there is almost no information on prevalence. There are many 
reasons for this, including: users can purchase them through internet websites and largely 
avoid interception by law enforcement agencies; new substances are not immediately 
included in household or other surveys of drug use in the population, in some cases because 
their prevalence is so low; and many users of NPS may not know exactly what it is that they 
are consuming. 
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During the collection of data for that original index of fatal toxicity (T) based on deaths 
related to prescriptions (King and Moffat, 1983) it was noted that: “… the mortality statistics 
provide a second, albeit crude, measure of drug toxicity. The index T is found to be related to 
the proportion of deaths involving a given drug where that drug was not in association with 
other drugs. For example, 72 per cent of deaths associated with pentobarbitone (T = 65.8) 
were not associated with other drugs whereas only 23 per cent of deaths associated with 
diazepam (T = 1.8) did not involve other drugs.” 
 
If we imagine a substance that has an extremely low fatal toxicity, then amongst a population 
of suspected fatal poisonings it will occur rarely and will mostly be associated with other 
more toxic substances that are the direct cause of death. If we determine the number of cases 
where it is the sole mention (S) on death certificates and those where it is mentioned 
alongside other substances (A), then the ratio S/A will be low. On the other hand, if we have 
a substance that is highly toxic, then its mere presence will often be associated with the direct 
cause of death, and the ratio S/A will be higher. Thus S/A should be a measure of the intrinsic 
fatal toxicity of a substance. 
 
It could be argued that the detection of a substance in post mortem tissues is subject to many 
distorting factors. This is particularly true with new drugs where a toxicology laboratory may 
not be able to detect certain substances perhaps because there are no suitable pure reference 
standards. Secondly, the toxicological examination may not be exhaustive, but allows 
analysis to be halted once one or more likely candidates have been found. However, by 
taking the ratio S/A, such selection effects should be reduced. The mention of a drug in the 
“cause of death” field on a death certificate does not necessarily indicate that substance was a 
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direct cause of death; it may have been a contributory factor, or it may have been a 
combination of substances that led to death. Some of the fatal cases recorded by the Office 
for National Statistics (ONS) may not have been poisonings in the normal sense because their 
definition includes cases of intoxication, dependence, drug withdrawal, etc. (ONS, 2017a). In 
other words, in this paper, lethal toxicity needs to be interpreted in a broad sense. This is 
particularly true for cannabis, which has only rarely been the direct cause of any death, but 
nevertheless features in a number of deaths where no other substance was mentioned (Ghodse 
et al., 2007). Furthermore, these figures do not include cases where drugs may have been 
involved in other ways, such as impairing judgement or perception of risk (e.g. drowning, fall 
from height, hyperthermia, road traffic accidents), or causing psychiatric problems (e.g. 
suicide using mechanical means), or even homicide. The numbers of deaths attributed to 
specific substances are likely to be under-estimates since about 10% of UK drug poisoning 
deaths are recorded in ambiguous terms such as “multiple drug overdose” without specifying 
the substances actually implicated in or contributing to death. A further difficulty, 
experienced in respect of NPS, is that the name of the specific molecule may not be properly 
communicated to ONS (see Table 1). 
 
Table 1 about here 
 
The advantage of using the ratio S/A is that it relies solely on the information on death 
certificates, and does not require any knowledge of availability. It could therefore be useful 
for evaluating the fatal toxicity of NPS. The purpose of this paper is to test that hypothesis. 
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Methods 
Data related to deaths registered in England and Wales between 1993 and 2016 were 
either extracted from the mortality statistics published by ONS (2017a) or extracted 
specifically for this study (ONS, 2015, 2016a, 2016b, 2016c, 2017b), where the 
selected substances were implicated in the cause of death. The principal substances 
examined were: amphetamine; cannabis; cocaine/crack; ecstasy; heroin; ketamine; 
and mephedrone. Table 1 lists those drugs that come under the ONS definition of 
NPS. Table 2 lists the number of deaths classified as ‘sole mentions’ (S), while Table 
3 lists the ‘any mentions’ (A). In respect of deaths involving ‘any mention’, other 
substances present may or may not have been psychoactive. In both Tables 2 and 3, 
substances are included where sufficient data were available (minimum of 10 deaths). 
Amongst NPS, this included AMT (α-methyltryptamine), benzodiazepine analogues, 
benzofurans, GHB/GBL (γ-hydroxybutyric acid/γ-butyrolactone), MPA 
(methiopropamine), novel amphetamines, piperazines, PMA (para-
methoxyamphetamine; 4-MA; 4-methoxyamphetamine)/ PMMA (para-methoxy-N-
methylamphetamine), synthetic cathinones (other than mephedrone) and synthetic 
cannabinoids. There were insufficient data to examine the fatal toxicity of specific 
synthetic cannabinoids. The term ‘amphetamines’ mostly relates to amphetamine (α-
methylbenzeneethanamine) itself. Although the word ‘ecstasy’ may be used rather 
broadly, it is taken here to mean 3,4-methylenedioxymethylamphetamine (MDMA). 
The mortality statistics refer to ‘heroin and morphine’ as a category. Since heroin is 
rapidly metabolised to morphine, post mortem analysis will rarely differentiate the 
two. Nevertheless, most of these deaths will have followed use of (illicit) heroin rather 
than (pharmaceutical) morphine, so in the present paper this is listed as ‘heroin’. 
Mephedrone and other synthetic cathinones as a wider class are both examined. 
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Deaths associated with ketamine or GHB/GBL are believed to be almost entirely a 
consequence of the use of illicit preparations rather than prescription medicines. 
Finally, crack cocaine is not usually distinguished from powder cocaine on death 
certificates, so figures for deaths comprise both substances. For the period in question, 
the number of users of crack cocaine was less than 10% of all cocaine users 
(Broadfield, 2017). 
 
Table 4 shows the estimated number of last year users (aged 16-59 years) of the 7 
principal substances as derived from the British Crime Survey Drug Misuse Declared 
(BCS), now known as the Crime Survey for England and Wales (CSEW; Broadfield, 
2017).  In Table 4, the use of cocaine is taken as any use of cocaine and/or crack. The 
mean estimated number of amphetamine users excludes the minor contribution of 
methylamphetamine, which was only recorded since 2008. In the case of ketamine, 
although mortality data were available for the period 1993-2016, prevalence data only 
started in 2006. For this reason, analysis was based on the 11 years from 2006. With 
mephedrone and synthetic cathinones more generally, mortality and prevalence 
estimates only related to the seven years 2010-2016. For piperazines and GHB/GBL, 
prevalence data were available only for one or two years (2010/11 and 2011/12; and 
2011/12 respectively). 
 
Seizures of selected substances made by law enforcement agencies in England and 
Wales for the period 2000-2015/6 (Hargreaves and Smith, 2016) are given in Table 5. 
Most of the data are derived from published sources, but some were specially 
extracted for this study. It should be noted that the statistics moved from a calendar 
year to a financial year in 2006/7, hence the change in date format. 
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Although the earlier index (King and Corkery, 2010) made use of other measures of 
availability, in the present study it was found that prevalence in the form of household 
surveys as summarised in the BCS/CSEW, and law enforcement seizures were the 
best measures. Furthermore, there are no recent estimates of market size for most of 
the drugs examined in this study; the estimates used here can be found in King and 
Corkery (2010). 
 
Tables 2 - 5 about here 
 
The index of fatal toxicity as defined by King and Corkery (2010), here named as Tf, 
was recalculated for each substance where data were available. The index of fatal 
toxicity (Tf) was defined as the mean number of deaths per annum (sole mentions) 
divided by the availability of that drug, where availability could be the mean number 
of users, the mean number of seizures per annum, or the market size. 
 
The calculation of Tf proceeds as follows: 
 
If Tf (H) is the fatal toxicity of heroin, which will be defined as 1000, then 
 
Tf (H) = [D(H) x F]/A(H)  = 1000 
 
where D(H) is the number of deaths associated with heroin (sole mentions), A(H) is 
the availability of heroin, measured either by the number of users, the number of 
seizures or some other metric, and F is a numerical factor that is unique to the 
particular type of availability measure. 
 10 
 
The fatal toxicity of some other substance (Z) is then given by 
 
Tf (Z) = [D(Z) x F]/A(Z)   
 
where D(Z) is the number of deaths associated with substance Z (sole mentions) and 
A(Z) is the appropriate availability measure of Z.  
 
Prevalence data in the BCS/CSEW were only available from 2001/2, so values of Tf 
were calculated using the average number of deaths in the 16 year period 2001 to 
2016 or, where appropriate, for shorter periods as noted above. As before, the index 
was then normalised such that heroin = 1000.. A Napierian logarithmic (Ln) transform 
was then used. This was necessary for graphical purposes because of the wide range 
in values of the index Tf. However, this was quite arbitrary since using the cube root 
of the index, for example, produced broadly similar scale compression Tf values for 
seizures and market size were calculated in a similar way. For combined parameters 
Tf values were calculated by obtaining the mean of the indices for the individual 
parameters (King and Corkery, 2010), then the Naperian logarithmic transforms were 
applied. 
 
 Results and Discussion 
Tables 6(a) to 6(e) show the index Tf for the original five substances (amphetamine, 
cannabis, cocaine/crack, heroin, and MDMA) based on: (a) prevalence; (b) number of 
seizures; (c) a combination of prevalence and number of seizures; (d) market size and 
finally (e) a combination of prevalence, number of seizures and market size. When 
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compared to the original (King and Corkery, 2010) values of LnTf , the Pearson 
product moment correlation coefficients (r) for each of these five measures of the 
index (as LnTf)  were all greater than 0.96, and values of P, the probability of the null 
hypothesis, were less than 0.01 in all cases. For all subsequent analyses, values of Tf 
were based on deaths related to the combination of prevalence and number of 
seizures. 
 
Table 6 about here 
 
Table 7 lists values of Sole (S) and Any (A) deaths as well as the ratio S/A for the 
period 1993-2016, or as otherwise indicated, for the reference compounds and NPS or 
groups of NPS (α-methyltryptamine, benzodiazepine analogues, benzofurans, 
GHB/GBL, ketamine, mephedrone, methiopropamine, novel amphetamines, para-
methoxyamphetamine/para-methoxy-N-methylamphetamine, piperazines, synthetic 
cathinones (other than mephedrone) and synthetic cannabinoids). 
 
Table 7 about here 
 
Figure 1 shows the relationship between the updated index Tf [based on a combination 
of prevalence and number of seizures; see Table 6(c)] and values of S/A (see Table 8) 
(r = 0.922; P <0.01) for the seven reference compounds (amphetamine, cannabis, 
cocaine, heroin, ketamine, MDMA and mephedrone). The straight line is the least 
squares fit [LnTf  = 11.12(S/A) - 0.48]. 
 
Figure 1 about here 
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Since sufficient data had been available to calculate values of Tf for ketamine and 
mephedrone, their inclusion in this group provides a cross-check on the indirect 
calculation of Tf from their S/A values using the above linear relationship. Thus, for 
ketamine the value of LnTf calculated from deaths / (prevalence + seizures) was 3.47 
whereas the value interpolated from Figure 1 was 4.13. For mephedrone, the value of 
LnTf calculated from deaths /(prevalence + seizures) was 3.52 whereas the value 
interpolated from Figure 1 was 1.73. As will be seen from Figure 1, the high value of 
LnTf for mephedrone appears anomalous, whereas the value interpolated from S/A 
seems more consistent with other substances, and particularly with synthetic 
cathinones (other than mephedrone) where the interpolated value of LnTf was 1.95 
(Table 7). 
 
The results shown in Figure 1 confirm the original hypothesis that the ratio S/A is a 
measure of the fatal toxicity of a substance. Because of limitations in the data, as 
discussed below, values of S/A, as shown in Table 7, should not be over-interpreted. 
Many NPS are based on what might be termed ‘amphetamine-type drugs’. It was 
found that substituted phenylisopropylamines had broadly similar fatal toxicities (i.e. 
S/A) compared to MDMA and amphetamine, but the fatal toxicity of ‘novel 
amphetamines’ was low. However, small differences in the estimated fatal toxicity of 
this group may not be significant. However, benzodiazepine analogues (BZD) had 
particularly low values of S/A. By contrast GHB/GBL and synthetic cannabinoid 
receptor agonists (SCRAs) had higher toxicities. 
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There are a number of limitations in the original data. For example, it is believed that 
prevalence, as assessed by BCS/CSEW, may underestimate the number of users of 
heroin and crack cocaine as well as those who do not live in normal domestic 
premises. For GHB/GBL and piperazine derivatives, prevalence data were only 
available for one or two years respectively, but as more data accumulate a future 
analysis should enable estimates of Tf to be made for these substances. In respect of 
NPS, and despite the public concern about their toxicity, there have still been 
relatively few fatal poisonings, especially for ‘sole mentions’, when compared with 
more established drugs of misuse. The role of alcohol as a contributory factor in some 
of the deaths is unknown, and has not been taken into account here. (The ONS only 
recently started publishing data for deaths involving alcohol but no other substance 
(ONS, 2017a)). Finally, the fatality index treats all users of a drug as an equivalent 
point. That is to say, the index relates to an ‘average’ user. Those who regularly 
consume more of a drug on each occasion compared to another user are probably at 
greater risk of a fatal outcome, but there is no reliable information on what constitutes 
occasional/regular or heavy/light use for most of the substances considered here. 
 
Conclusions 
This analysis supports the hypothesis that the ratio S/A is a meaningful measure of 
fatal toxicity. Bearing in mind the limited mortality and prevalence data available for 
some new substances, it is suggested that the fatal toxicity of benzodiazepine 
analogues (BZD) was particularly low. By contrast GHB/GBL, synthetic cannabinoid 
receptor agonists (SCRAs), benzofurans and AMT had higher toxicities. It is expected 
that the analysis shown here could be improved as more mortality and prevalence data 
become available. 
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Table 1. ONS definitions of NPS categories 
 
NPS category Substances 
Benzodiazepine analogues Diclazepam, Etizolam, Flubromazepam, 
Flubromazolam, Phenazepam, Pyrazolam,  
Benzofurans 1-(Benzofuran-5-yl)-N-methylpropan-2-amine, 1-
(Benzofuran-5-yl)-propan-2-amine, 1-(Benzofuran-6-
yl)-propan-2-amine, APB(1), APDB(2), 5-EAPB 
Cathinones Butylone, Cathine, Cathinone,  Fluoromethcathinone, 
4- Mephedrone, Methoxymethcathinone, 
Methylenedioxypyrovalerone, Methylethcathinone,  
Methylone   
NBOMes 25B-NBOMe, 25C-NBOMe, 25I-NBOMe 
Novel amphetamines 2-Aminoindane, Fluoromethamphetamine, 4- 
MDDA(3), Methylamphetamine 
Novel opiates Acetylfentanyl, AH-7921, U-47700 
Piperazines BZP, Piperazine(4), TFMPP 
Synthetic cannabinoids 5F-ADB(5), 5F-AKB-48, 5F-PB-22(6), AB-
CHMINACA, MDMB-CHMICA, Synthetic 
cannabinoid 
Notes: 
There was uncertainty in some cases as to which specific molecule was meant as ONS 
did not receive toxicological information and relied solely on the text give in the 
cause of death field on the death certificate or in any supplementary information given 
by the coroner, e.g. in their findings or ‘verdict’. 
(1) “Aminopropyl Benzofuran” was stated in the majority of cases, but some just 
stated APB. The specific isomer was unknown. 
(2) “APDB” was all that was mentioned on the death certificate. The specific 
isomer was unknown. 
(3) “MDDA” was all that was written on the death certificate. This is presumed to 
mean MDDM aka MDDMA 
(4) The term “piperazine” almost certainly referred to a substituted piperazine. 
(5) “5F-ADB” aka “5F-MDMB-PINACA”. 
(6) In all cases, all that was on the death certificate was “5F-PB-22”. This was 
presumed to refer to the indole analogue. 
 
Source: Personal communication to JC from Mortality Team, Office for National 
Statistics, 14 and 31 August 2017 
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Table 2. Deaths registered in England and Wales for the period 1993 - 2016 where selected substances were implicated in the cause of death (sole mentions).  
 
Substance/ Year 
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2
0
1
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2
0
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2
0
1
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2
0
1
6
 Total Years of 
exposure 
Mean 
Amphetamine 5 4 5 5 4 3 4 14 12 17 16 21 27 19 27 29 22 28 26 22 18 33 41 44 446 24 18.58 
AMT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 4 3 4 0 14 24 0.58 
Benzodiazepine 
analogues 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 2 8 0.25 
Benzofurans 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 4 1 0 7 6 1.17 
Cannabis 5 5 5 4 6 2 4 0 0 0 1 1 2 2 1 2 1 2 1 0 1 7 4 3 59 24 2.46 
Cocaine/crack 0 3 3 4 5 12 15 40 40 41 44 49 54 71 84 86 73 59 34 39 46 74 88 108 1,072 24 44.67 
GHB/GBL 0 0 0 1 0 0 2 1 0 2 2 0 2 4 3 13 12 6 10 8 10 12 10 20 118 23 5.13 
 
Heroin 110 138 185 216 233 277 345 663 725 621 481 492 566 497 588 587 562 487 332 305 424 492 603 588 10,517 24 438.21 
Ketamine 0 0 0 0 0 0 1 1 1 1 0 0 0 1 3 4 7 4 7 3 2 5 1 7 48 18 2.67 
MDMA 9 10 10 8 8 10 6 10 26 24 29 24 33 27 28 15 13 5 7 13 28 25 24 32 424 24 17.67 
Mephedrone n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0 2 1 4 1 2 12 2 24 8 3.00 
 
MPA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 3 1 1 6 5 1.20 
Novel 
amphetamines 
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0 0 0 0 0 0 1 0 0 0 0 1 11 0.09 
Piperazines n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1 2 1 0 4 0 0 0 0 8 9 0.89 
PMA/PMMA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 11 14 12 6 2 45 24 1.88 
Synthetic 
cannabinoids 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 6 14 22 8 2.75 
 
Synthetic 
cathinones 
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0 2 2 7 5 2 12 4 34 8 4.25 
 
 
Note: n/a = not available  
 
Sources: ONS (2015, 2016a, 2016b, 2016c, 2017a, 2017b) 
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Table 3. Deaths registered in England and Wales for the period 1993 - 2016 where selected substances were implicated in the cause of death (any mentions). 
Substance/ Year 
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 Total Years of 
exposure 
Mean 
Amphetamine 37 19 35 33 41 48 67 40 28 51 33 43 50 49 50 59 50 48 46 49 56 85 90 96 1,203 24 50.13 
AMT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 7 6 5 0 22 24 0.92 
Benzodiazepine 
analogues 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 4 3 14 11 10 44 8 5.50 
 
Benzofurans 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 7 5 2 3 20 6 3.33 
 
Cannabis 13 19 16 9 14 10 8 9 16 13 11 19 19 17 12 19 22 11 7 14 11 28 21 24 362 24 15.08 
Cocaine/crack 11 24 22 13 27 65 88 83 97 128 129 154 176 190 196 235 202 144 112 139 169 247 320 371 3,342 24 139.25 
GHB/GBL 0 0 0 1 0 0 3 3 1 5 6 1 4 7 9 20 16 12 20 13 18 20 26 30 215 23 9.35 
 
Heroin 155 270 331 440 444 609 755 851 981 865 696 751 842 713 829 897 880 791 596 579 765 952 1,201 1,209 17,402 24 725.08 
Ketamine 0 0 0 0 0 0 1 2 2 1 3 1 0 2 6 8 15 6 11 12 9 19 7 12 117 18 6.50 
MDMA 12 20 17 16 15 17 21 28 55 56 50 43 58 48 47 44 27 8 13 31 43 50 57 63 839 24 34.96 
Mephedrone n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0 6 5 12 18 22 44 15 122 8 15.25 
 
MPA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 4 7 6 10 29 5 5.80 
Novel 
amphetamines 
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0 0 0 0 0 0 1 3 4 1 1 10 11 0.91 
Piperazines n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 5 9 6 2 9 1 2 0 0 34 9 3.78 
PMA/PMMA 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 20 29 24 10 3 88 24 
 
3.67 
Synthetic 
cannabinoids 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 8 27 38 8 4.75 
 
Synthetic 
cathinones 
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0 6 6 18 26 27 49 25 157 8 19.63 
 
Note: n/a = not available 
 
Sources: ONS (2015, 2016a, 2016b, 2016c, 2017a, 2017b)
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Table 4. Estimated number (thousands) of individuals aged 16-59 who had used selected substances in the last year in England and Wales, 2001/2-
2016/7 
 
Substance/Year 
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 Mean 
Amphetamines 460 475 470 426 423 421 327 376 297 323 247 205 246 193 198 145 327.00 
Cannabis 3185 3281 3271 2984 2732 2597 2367 2471 2077 2147 2191 2038 2144 2174 2121 2177 2497.31 
Cocaine/crack 634 687 788 660 817 891 782 995 827 721 731 659 816 790 756 779 770.81 
Any cocaine 587 635 754 638 770 840 743 949 786 682 699 628 777 756 738 764 734.13 
GHB/GBL n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 47 n/a n/a n/a n/a n/a 47.00 
Heroin 44 44 42 38 39 42 35 29 33 34 46 27 34 21 27 15 34.38 
Ketamine n/a n/a n/a n/a n/a 93 112 178 151 197 185 117 195 159 94 116 145.18 
MDMA 634 596 595 549 499 567 470 567 496 434 445 403 516 545 492 439 515.44 
Mephedrone n/a n/a n/a n/a n/a n/a n/a n/a n/a 345 375 167 211 162 89 48 199.57 
Piperazines n/a n/a n/a n/a n/a n/a n/a n/a n/a 34 47 n/a n/a n/a n/a n/a 40.50 
Notes: n/a = not available; no earlier data available for this age-range. 
Sources: Home Office, 2012; Broadfield, 2017 
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Table 5. Total seizures of selected substances made by police forces and Customs & Excise/Border Force in England and Wales for the period 2000 – 2015/6. 
Substance/ 
Year 
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2
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 Total Years of 
exposur
e 
Mean 
Cocaine  5,582  6,797 6,015 7,251 8,279 12,512 16,917 21,346 24,659 21,377 17,710 17,596 16,758 16,825 15,815 15,588  231,027            16   14,439  
MDMA  8,337  9,080 7,044 6,475 6,256 6,688 8,184 7,173 5,218 3,724 2,537 3,200 3,224 3,237 3,018 2,906    86,300  16   5,394  
Heroin 13,71
3  
15,44
7 
13,35
7 
11,19
5 
11,66
8 
14,072 13,942 14,186 13,302 12,836 10,821 9,182 8,573 8,579 7,892 8,050  186,813  16  11,676  
Total 
cannabis 
85,08
7  
80,65
4 
82,51
9 
87,51
2 
81,51
7 
120,42
7 
144,59
9 
173,58
9 
186,14
7 
176,83
0 
167,41
0 
175,26
4 
157,20
8 
149,08
7 
124,40
8 
109,52
7 
2,101,78
6  
16 131,36
2  
Amphetamin
e 
 6,390  6,348 6,181 6,208 6,504 7,837 8,477 8,863 7,760 7,302 7,185 6,773 5,934 6,067 5,530 4,418  107,778  16    6,736  
GHB only  n/a  n/a  n/a  29 21 29 61 63 47 59 66 45 61 41 75 64         661  13         51  
Ketamine  n/a n/a n/a n/a n/a n/a   n/a  n/a 1,269 1,612 1,793 1,543 1,527 1,621 485 530    10,380  8    1,298  
Piperazines 
(substituted) 
n/a n/a n/a n/a n/a n/a n/a n/a n/a 157 830 398 142 194 92 42      1,855  7       265  
Mephedrone n/a n/a n/a n/a n/a n/a n/a n/a n/a 35 2,002    2,461     3,850  3073   2,325     1,031     14,777  7    2,111  
 
Notes: n/a = not controlled 
  
Sources: Smith (2008); Hargreaves and Smith (2016); personal communication to JC from J. Hargreaves, Home Office Crime and Policing Analysis Unit, 24 November 2016 
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Table 6. Overall Index (Tf) of fatal toxicity for the period 2001/2 to 2016 
 
(a) [Prevalence only] 
Substance Index (any mention) Index (sole mention) Overall Index Ln (Overall Index) 
Heroin 1000.00 1000.00 1000.00 6.91 
Cocaine & crack 9.91 5.29 7.60 2.03 
Amphetamine 6.85 5.06 5.96 1.79 
MDMA 3.41 2.82 3.12 1.14 
Cannabis 0.27 0.05 0.16 -1.83 
GHB/GBL 11.23 9.99 10.61 2.36 
Ketamine 1.99 1.30 1.65 0.50 
Piperazines 3.79 1.45 2.62 0.96 
Mephedrone 3.10 0.99 2.05 0.72 
 
Note: The Overall index is the mean of the ‘sole’ and ‘any’ mention indices 
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(b) [Seizures] 
Substance Index (any mention) Index (sole mention) Overall Index Ln (Overall Index) 
Heroin 1000.00 1000.00 1000.00 6.91 
Cocaine & crack 132.29 70.62 101.46 4.62 
Amphetamine 112.98 83.45 98.22 4.59 
MDMA 110.74 91.51 101.13 4.62 
Cannabis 1.73 0.30 1.02 0.02 
GHB/GBL 3527.96 3137.06 3332.51 8.11 
Ketamine 75.73 49.57 62.65 4.14 
Piperazines 196.59 75.05 135.82 4.91 
Mephedrone 99.62 31.79 65.17 4.18 
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(c) [Prevalence & Seizures] 
Substance Index (any mention) Index (sole mention) Overall Index Ln (Overall Index) 
Heroin 1000.00 1000.00 1000.00 6.91 
Cocaine & crack 71.10 37.95 54.53 4.00 
Amphetamine 59.92 44.25 52.09 3.95 
MDMA 57.07 47.17 52.12 3.95 
Cannabis 1.00 0.17 0.59 -0.53 
GHB/GBL 1969.59 1573.52 1771.56 7.48 
Ketamine 38.86 25.44 32.15 3.47 
Piperazines 100.19 38.25 69.22 4.24 
Mephedrone 51.36 16.39 33.88 3.52 
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(d) [Market size] 
Substance Index (any mention) Index (sole mention) Overall Index Ln (Overall Index) 
Heroin 1000.00 1000.00 1000.00 6.91 
Cocaine & crack 93.02 49.65 71.34 4.27 
Amphetamine 127.46 94.15 110.81 4.71 
MDMA 78.80 65.12 71.96 4.28 
Cannabis 0.38 0.07 0.23 -1.47 
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 (e) [Prevalence, Seizures & Market size] 
Substance Index (any mention) Index (sole mention) Overall Index Ln (Overall Index) 
Heroin 1000.00 1000.00 1000.00 6.91 
Cocaine & crack 51.13 26.53 38.83 3.66 
Amphetamine 45.05 31.83 38.44 3.65 
MDMA 41.21 33.05 37.13 3.61 
Cannabis 0.68 0.12 0.40 -0.92 
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Table 7. Mean values of Sole (S) and Any (A) mentions, and S/A where selected 
substances were implicated in the cause of death registered in England and Wales for 
the period 1993 - 2016 or as otherwise shown. Values of LnTf have been interpolated 
from Figure 1 for those substances where LnTf was unavailable directly because of 
lack of prevalence/seizure data. Substances with high interpolated values of LnTf (>4) 
are shown emboldened, whereas substances with low values (<2) are shown in italics. 
Substance Years of exposure S A S/A LnTf 
Amphetamine 24 18.58 50.13 0.371 - 
AMT 24 0.58 0.92 0.630 6.59 
Benzodiazepine analogues 8 0.25 5.50 
 
0.045 -0.02 
Benzofurans 6 1.17 
 
3.33 
 
0.351 3.46 
Cannabis 24 2.46 15.08 0.163 - 
Cocaine/crack 24 44.67 139.25 0.321  
GHB/GBL 23 5.13 
 
9.35 
 
0.549 5.68 
Heroin 24 438.21 725.08 0.604 - 
Ketamine 18 2.67 6.50 0.411 - 
MDMA 24 17.67 34.96 0.505 - 
Mephedrone 8 3.00 
 
15.25 
 
0.197 - 
MPA 5 1.20 5.80 0.207 1.84 
Novel amphetamines 11 0.09 0.91 0.100 0.64 
Piperazines 9 0.89 3.78 0.235 2.16 
PMA/PMMA 24 
 
1.88 3.67 0.497 5.09 
Synthetic cannabinoids 8 2.75 
 
4.75 
 
0.579 6.02 
Synthetic cathinones 8 4.25 
 
19.63 0.217 1.95 
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Figure 1. The relationship between the updated index LnTf [based on a combination 
of prevalence and number of seizures; see Table 6 (c)] and values of S/A (see Table 7) 
(r = 0.923; P <0.01) for the seven reference compounds (amphetamine, cannabis, 
cocaine, heroin, ketamine, MDMA and mephedrone). The straight line is the least 
squares fit [LnTf  = 11.22(S/A) - 0.48]. 
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